Key Points
- Shares of Soleno Therapeutics (SLNO) jumped more than 30% during premarket hours Monday following acquisition reports
- Neurocrine Biosciences (NBIX) is reportedly close to finalizing a deal to buy Soleno for over $2.5 billion
- The proposed acquisition could price SLNO shares in the low-to-mid $50 range
- According to the Financial Times, an agreement may be reached as early as Monday, April 6
- Shares of Neurocrine dipped 0.4% premarket following the acquisition news
It’s been a challenging year for Soleno Therapeutics investors, with the stock sliding approximately 14% since January. However, Monday morning brought a dramatic reversal of fortune.
Soleno Therapeutics, Inc., SLNO
According to a Financial Times report, Neurocrine Biosciences has entered late-stage negotiations to acquire the rare disease-focused biotechnology company in a transaction exceeding $2.5 billion. News of the potential deal triggered a sharp 30%+ rally in SLNO shares before the opening bell.
Based on the reported terms, Soleno shareholders could receive somewhere in the low-to-mid $50s per share. The FT indicated that negotiations are progressing rapidly, with the possibility of an announcement coming as soon as today.
The centerpiece of Soleno’s portfolio is Vykat XR, which received approval and launched commercially last year. The medication addresses hyperphagia, an overwhelming and chronic hunger condition associated with Prader-Willi syndrome. Patients suffering from hyperphagia face serious health risks including gastric rupture, choking hazards, severe obesity, and heart disease.
Prader-Willi syndrome affects approximately one in 15,000 newborns, making it a rare genetic condition. Vykat XR represents the first approved treatment specifically targeting the insatiable appetite symptoms characteristic of this syndrome.
Industry analysts have projected Vykat XR could generate peak sales approaching $2.3 billion annually — a compelling revenue opportunity that appears to have attracted Neurocrine’s interest.
Neurocrine’s Strategic Expansion
With a current market valuation near $13.21 billion, Neurocrine Biosciences has built its business around treatments like Ingrezza, which addresses abnormal involuntary movements associated with Huntington’s disease, alongside other marketed products and pipeline assets.
Acquiring Vykat XR would represent Neurocrine’s entry into the rare disease and orphan drug market, a sector characterized by favorable pricing dynamics and typically fewer competitive pressures.
Shares of Neurocrine declined 0.4% in premarket activity Monday. Such modest selloffs are common when acquirers announce deals, as the market factors in the premium being offered.
Putting SLNO’s Surge in Perspective
Despite Monday’s dramatic premarket gain, Soleno had been underperforming in 2026, down roughly 14% year-to-date before this week. The stock had languished despite bullish analyst projections for Vykat XR’s commercial trajectory.
According to TipRanks, SLNO carries a Strong Buy rating from a consensus of 11 analysts. The mean price target stands at $101.09, with the most optimistic forecast reaching $125.
If the transaction closes at the reported valuation in the low-to-mid $50s per share, it would represent a significant discount to analyst expectations — though it would still deliver a meaningful premium compared to Soleno’s recent trading levels.
The Financial Times report relied on unnamed sources with knowledge of the negotiations, emphasizing that talks are advancing quickly and appear to be nearing completion.
